Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vabysmo
Pharma
Regeneron faces category headwinds for eye disease drug Eylea
In its fourth-quarter presentation, Regeneron said that the slide in sales for its Eylea franchise will continue in the first quarter of this year.
Kevin Dunleavy
Jan 30, 2026 11:41am
Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop
Jan 29, 2026 11:23am
Regeneron wins 2 Eylea nods, ramping up competition with Roche
Nov 20, 2025 11:53am
Roche overcomes drug-specific struggles, currency woes in Q3
Oct 23, 2025 12:15pm
Settlement allows Sandoz to launch Eylea biosimilar in late 2026
Sep 9, 2025 10:30am
Manufacturing issues cause FDA to delay decisions on Eylea HD
Aug 20, 2025 2:32pm
